{"id":"bms-986205","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":{"chemblId":"CHEMBL4298147","moleculeType":"Small molecule","molecularWeight":"507.03"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The NLRP3 inflammasome is a multi-protein complex that activates caspase-1, leading to production of pro-inflammatory cytokines IL-1β and IL-18. By selectively inhibiting NLRP3, BMS-986205 dampens pathological inflammation without broadly suppressing immune function. This mechanism is relevant to inflammatory and autoinflammatory diseases where NLRP3 activation drives disease pathology.","oneSentence":"BMS-986205 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:44.057Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT03661320","phase":"PHASE3","title":"A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2018-11-06","conditions":"Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer","enrollment":855},{"nctId":"NCT04106414","phase":"PHASE2","title":"Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-09-24","conditions":"Endometrial Adenocarcinoma, Endometrial Carcinosarcoma","enrollment":24},{"nctId":"NCT04047706","phase":"PHASE1","title":"Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2019-08-13","conditions":"Glioblastoma","enrollment":18},{"nctId":"NCT03854032","phase":"PHASE2","title":"Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2019-04-09","conditions":"Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx","enrollment":45},{"nctId":"NCT03459222","phase":"PHASE1, PHASE2","title":"An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-05-30","conditions":"Advanced Cancer","enrollment":229},{"nctId":"NCT02658890","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-04-14","conditions":"Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer","enrollment":627},{"nctId":"NCT03695250","phase":"PHASE1, PHASE2","title":"BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer","status":"TERMINATED","sponsor":"Edward Kim","startDate":"2018-10-16","conditions":"Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8","enrollment":8},{"nctId":"NCT02935634","phase":"PHASE2","title":"A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-11-29","conditions":"Advanced Gastric Cancer","enrollment":190},{"nctId":"NCT03519256","phase":"PHASE2","title":"A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2018-08-02","conditions":"Urinary Bladder Neoplasms","enrollment":142},{"nctId":"NCT02996110","phase":"PHASE2","title":"A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-02-02","conditions":"Advanced Cancer","enrollment":182},{"nctId":"NCT03335540","phase":"PHASE1","title":"An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-05-07","conditions":"Advanced Cancer","enrollment":20},{"nctId":"NCT03792750","phase":"PHASE1, PHASE2","title":"A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-12-31","conditions":"Advanced Cancer","enrollment":12},{"nctId":"NCT03329846","phase":"PHASE3","title":"An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-11-30","conditions":"Melanoma, Skin Cancer","enrollment":20},{"nctId":"NCT02750514","phase":"PHASE2","title":"An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2016-05-09","conditions":"Advanced Cancer","enrollment":295},{"nctId":"NCT04007588","phase":"PHASE2","title":"A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-09-06","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":""},{"nctId":"NCT03936374","phase":"PHASE1","title":"A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-05-08","conditions":"Healthy","enrollment":16},{"nctId":"NCT03386838","phase":"PHASE3","title":"An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-28","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT03192943","phase":"PHASE1","title":"A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-06-23","conditions":"Advanced Cancer","enrollment":11},{"nctId":"NCT03374228","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of BMS-986205","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-01-04","conditions":"Healthy Participants","enrollment":7},{"nctId":"NCT03417037","phase":"PHASE3","title":"An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2018-05-24","conditions":"Lung Cancer, Non-Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03346837","phase":"PHASE1","title":"A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-11-22","conditions":"Malignancies Multiple","enrollment":53},{"nctId":"NCT03378310","phase":"PHASE1","title":"A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-12-21","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT03362411","phase":"PHASE1","title":"A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-11-09","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT03312426","phase":"PHASE1","title":"An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-10-09","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT03247283","phase":"PHASE1","title":"Pharmacokinetics and Metabolism Study in Healthy Male Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-07-19","conditions":"Cancer","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Linrodostat"],"phase":"phase_3","status":"active","brandName":"BMS-986205","genericName":"BMS-986205","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Biologic","firstApprovalDate":"","aiSummary":"BMS-986205 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity. Used for Acute coronary syndrome, Chronic kidney disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":18,"withResults":8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}